An Analysis of United States Food and Drug Administration Warning Letters Issued to Clinical Investigators from 1996 through 2011

&
Journal of Clinical Research and Bioethics 2 (8) (2011)
  Copy   BIBTEX

Abstract

This article has no associated abstract. (fix it)

Categories

Keywords

Reprint years

DOI

10.4172/2155-9627.1000122

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,322

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Evaluating the First-in-Human Clinical Trial of a Human Embryonic Stem Cell-Based Therapy.Audrey R. Chapman & Courtney C. Scala - 2012 - Kennedy Institute of Ethics Journal 22 (3):243-261.
OPRR and FDA propose revised expedited review categories.Helen McGough - 1997 - IRB: Ethics & Human Research 20 (1):9-11.
Clinical study reflections: Another view commentary on: “Raising suspicions with the food and drug administration: Detecting misconduct”.Patricia Spitzig - 2010 - Science and Engineering Ethics 16 (4):705-711.
Antagonistic Synergy: Process and Paradox in the Development of New Agricultural Antimicrobial Regulations. [REVIEW]Wesley R. Dean & H. Morgan Scott - 2005 - Agriculture and Human Values 22 (4):479-489.
Retail relations: an interlocking directorate analysis of food retailing corporations in the United States. [REVIEW]Rachel A. Schwartz & Thomas A. Lyson - 2007 - Agriculture and Human Values 24 (4):489-498.
Stimulating the development of drug treatments to improve cognition in schizophrenia.Micahel F. Green - manuscript
Raising Suspicions with the Food and Drug Administration: Detecting Misconduct.Michael R. Hamrell - 2010 - Science and Engineering Ethics 16 (4):697-704.
Speaking Off Label.Stephen R. Latham - 2010 - Hastings Center Report 40 (6):9-10.
A clinical trials manual from the Duke Clinical Research Institute: lessons from a horse named Jim.Margaret B. Liu - 2010 - Hoboken, NJ: Wiley-Blackwell. Edited by Kate Davis & Margaret B. Liu.
Race, Pharmacogenomics, and Marketing: Putting BiDil in Context.Jonathan Kahn - 2006 - American Journal of Bioethics 6 (5):W1-W5.
Fraud and Abuse: United States ex rel Merena v. SmithKline Beecham Corp.;1 United States ex rel Spear v. SmithKline Beecham Clinical Lab.;2 United States ex rel Grossenbacher v. SmithKline Beecham Clinical Lab. [REVIEW]Allyson Behm - 2000 - Journal of Law, Medicine and Ethics 28 (2):191-192.
Ethical concerns regarding commercialization of deep brain stimulation for obsessive compulsive disorder.Cordelia Erickson-Davis - 2012 - Bioethics 26 (8):440-446.
FAO 1996. The Sixth World Food Survey. (Food and Agriculuture Organization of the United Nations, Rome.).Daniel Sellen - 1999 - Journal of Biosocial Science 31 (1):139-144.
Cost‐effectiveness of an electronic medication ordering and administration system in reducing adverse drug events.Robert C. Wu, Audrey Laporte & Wendy J. Ungar - 2007 - Journal of Evaluation in Clinical Practice 13 (3):440-448.
On the Use of Animals in emergent embryonic Stem Cell Research for Spinal Cord Injuries.Andrew Fenton & Frederic Gilbert - 2011 - Journal of Animal Ethics 1 (1):37-45.

Analytics

Added to PP
2014-02-02

Downloads
24 (#637,523)

6 months
6 (#522,885)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references